7/27/2019 Flyer 11th European_v6

http://slidepdf.com/reader/full/flyer-11th-europeanv6 1/2

ITALY

20 22 MARCH, 2013

ROME

11th EUROPEAN MEETING ON

HIV & HEPATITIS 

Treatment Strategies & Antiviral Drug Resistance

Program Committee

Organizing Committee Bonaventura Clotet, MD, PhD

University Hospital Germans Trias i Pujol, Barcelona, Spain

Stephan Dressler, MD, PhD

European AIDS Treatment Group, Berlin, Germany

Anna Maria Geretti MD, PhDUniversity of Liverpool and University College London, United Kingdom

Claus Nielsen, MSc, PhD

Statens Serum Institut, Copenhagen, Denmark

Jean - Michel Pawlotsky, MD, PhD

Hôpital Henri Mondor, Paris, France

Jonathan Schapiro, MD

Sheba Medical Center, Tel Aviv, Israel

Jean-Claude Schmit MD, PhD

Centre Hospitalier de Luxembourg, Luxembourg

Target Audience

Meeting Objectives

Meeting Venue

The target audience of the 11th European Meeting on HIV

& Hepatitis consists of clinicians involved in daily care for 

infectious disease patients; scientists involved in antiviral

drug resistance, researchers and PhD students active in

this eld.

 - To gather professionsls in the eld of infectiousdiseases in an interactive workshop setting

 - To provide a platform for presentation and discussion

of the latest developments in the eld

 - To map all current studies and results

 - To translate new data to treatment guidelines

 - To educate clinicians on how to best implement current

and new drugs

Registration, additional information

www.virology-education.com

The meeting will be held at the Trevi Fountain Conference

Centre. Housed in the monumental palace of the Pontical

Gregorian University, the conference centre is located in the

very heart of Rome, a stone’s throw from its namesake the

Trevi Fountain and many other world - famous monuments.

INVITATION

 Free re gistrati  on for Y  oung In v estigat  o rs with accepte d abstr acts! 

7/27/2019 Flyer 11th European_v6

http://slidepdf.com/reader/full/flyer-11th-europeanv6 2/2

Preliminary program

Wednesday 20 March 2013 

10:00h –

12.00h

EucoHIV pre workshop training on HIV-1 tropism testing, in

collaboration with CHAIN and ESAR

Main Meeting Program 

14:00h Opening of the Workshop

Session 1 Clinical Challenges in HIV Therapy

14:15h Abstract – driven presentations

15:30h Coffee break

Session 2 Transmission and Evolution of Drug Resistance (HIV, HCV and HBV)

16:00h HIV Treatment: New and Veteran Drugs Classe

Jonathan Schapiro, MD, Sheba Medical Centre, Israel 

16:30h Abstract – driven presentations

17:15h Round table discussion: How to simplify HIV Therapy.

Clinical perspective: Andrea Antinori, MD, National Institute of Infectious

Diseases L. Spallanzani, Rome, Italy 

Virological perspective: Roger Paredes, MD, PhD, IrsiCaixa Foundation,

Spain

Community perspective: Stephan Dressler, MD, PhD, European AIDS

Treatment Group, Berlin, Germany 

18.00h End of Plenary Session 

Poster viewing and drinks

Guidelines meeting – closed meeting by ESAR

Thursday 21 March 2013 

Session 3 Clinical Challenges in Hepatitis C Therapy

08:30h Clinical Challenges in HCV Therapy

Christophe Hezode, MD, Hôpital Henri Mondor, Université Paris X, France

09:00h Treatment of HCV: when to start, when to wait

Jean-Michel Pawlotsky, MD, PhD, Hôpital Henri Mondor, Université Paris

 XII, France

09:30h Abstract – driven presentations

10:00h Clinical case presentation

10:30h Coffee break, poster viewing session

Session 4 HCV Drug Resistance

11:30h Baseline HCV variability in relation to DAA’s 

Maurizio Zazzi, MSc, University of Siena, italy 

12:00h Optimal virological monitoring of HCV Treatment

Jean-Michel Pawlotsky, MD, PhD, Hôpital Henri Mondor, Université Paris

 XII, France13:00h Lunch

14:00h MSD Satellite Symposium

15:30h Coffee break

Session 5 Round table discussion: Cost effectiveness of antiviral therapy

16:00h Introductory lecture

Valentina Cambiano, MSc, University College London, UK 

16:30h Clinical perspect ive: Bonaventura Clotet, MD, PhD, University Hospital 

Germans Trias i Pujol, Badalona, Spain

Virological perspective: Charles Boucher, MD, PhD, Erasmus Medical 

Centre, the Netherlands

Community perspective: s peaker to be confrmed 

18:00h End of plenary session

19.00 Workshop dinner 

Friday 22 March 2013 

Session 6

08:30h Break-out sessions

10:30h Coffee break, poster viewing session

Session 7 Round table discussion: Perspectives on HIV Eradication and Cure

11:00h Disrupting Latency 

David Margolis, MD, University of North Carolina, USA11:30h Immunological Control

Giuseppe Pantaleo, MD, Centre Hospitalier Universitaire Vaudois,

Switzerland 

12.00 Diagnosis/monitoring markers

Javier Martìnez – Picado, PhD, IrsiCaixa Foundation, Spain

12.30 Discussion

13.00 Closure of the meeting